Bullish indicating open at $55-$60, IPO prices at $37
Inozyme Pharma Inc. (INZY) stock has tumbled to a 52-week low, reaching a price level of just $1.23. This latest dip reflects a significant downturn for the biopharmaceutical company, which has seen its stock value plummet by 78.2% over the past year. Technical indicators from InvestingPro suggest the stock is in oversold territory, with analyst price targets ranging from $11 to $30, indicating potential upside opportunity. Investors have been grappling with a series of setbacks, including clinical trial results and market conditions that have not favored the biotech sector. The 52-week low marks a critical point for Inozyme Pharma as it navigates through a challenging phase. Despite these challenges, the company maintains a strong liquidity position with a current ratio of 7.68 and more cash than debt on its balance sheet. InvestingPro analysis reveals 12 additional key factors affecting INZY’s outlook.
In other recent news, Inozyme Pharma Inc. reported promising interim results from its ENERGY 1 trial and Expanded Access Program, showcasing improvements in survival rates and heart function for infants with ENPP1 Deficiency. The treatment, INZ-701, led to an 80% survival rate beyond the first year, a significant increase from the historical 50% rate, with no serious treatment-related adverse events reported. Additionally, Jefferies initiated coverage on Inozyme with a Buy rating, setting a price target of $26, and highlighted the potential of INZ-701, which is undergoing clinical trials for orphan disorders. The firm emphasized the drug’s promising results in normalizing pyrophosphate levels and improving exploratory endpoints in adults.
Meanwhile, Raymond (NSE:RYMD) James maintained an Outperform rating on Inozyme, albeit with a reduced price target of $24, citing concerns over anti-drug antibodies observed in the ENERGY 1 study. These antibodies, found at higher levels in infants, introduced uncertainty despite not fully counteracting the drug’s efficacy. The ENERGY 3 study, focusing on pyrophosphate levels, is expected to be closely monitored for the influence of these antibodies. Inozyme has also completed enrollment for its ENERGY 3 pivotal trial in pediatric patients, with topline data anticipated in early 2026. Furthermore, the company is preparing for its ASPIRE pivotal trial for ABCC6 Deficiency, with plans to initiate the study in early 2026 following regulatory guidance from the FDA and EMA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.